The North America High-Resolution Melting (HRM) Analysis Market is witnessing robust growth, driven by technological advances in precision medicine and genetic research. With increasing applications in oncology, rare disease detection, and infectious disease monitoring, the market is expected to expand at a strong CAGR of 7.4% from 2024 to 2035. The market size was valued at USD 420 Million in 2025 and is projected to reach USD 885 Million by 2035, highlighting the growing adoption of HRM analysis in clinical laboratories and research institutions across the region.
The economic impact of tariffs on "North America High-Resolution Melting Analysis Market".
Market Growth Drivers
Increasing Adoption of Precision Medicine: The drive towards tailored patient care in North America has accelerated the adoption of high-resolution melting analysis, particularly in genetic mutation screening and pharmacogenomics. Leading laboratory companies like Thermo Fisher Scientific have expanded their HRM assay portfolios to support healthcare providers focused on precision oncology. These technologies enable accurate genotyping, identification of single nucleotide polymorphisms, and mutation scanning—critical in developing personalized treatment plans and guiding therapy selection for cancer and inherited conditions.
Advancements in Molecular Diagnostic Techniques: Technological progress in real-time PCR platforms has made HRM analysis more accessible and efficient for clinical, pharmaceutical, and research settings. Companies like Bio-Rad Laboratories have launched next-generation qPCR instruments compatible with HRM analysis, enhancing the speed and throughput of DNA dissociation curve evaluation. This boost in diagnostic accuracy and reliability is fueling further adoption among hospitals, research labs, and biotechnology firms.
Market Trends
Integration of AI and Machine Learning for Enhanced Analysis: Companies such as Agilent Technologies are incorporating artificial intelligence and machine learning algorithms into HRM platforms. These advancements are streamlining data interpretation, reducing human error, and allowing the rapid analysis of large data sets. This trend is expected to reduce turnaround times for genetic testing and improve the scalability of HRM solutions, which is particularly valuable for population-scale studies and large clinical trials.
Expansion of HRM Applications Beyond Oncology: The HRM analysis market in North America is experiencing a shift as applications expand into infectious disease diagnostics and agricultural genomics. Firms like Roche have launched HRM kits focused on identifying viral and bacterial pathogens, supporting outbreak tracking and public health surveillance. Additionally, academic and commercial labs are leveraging HRM techniques for crop genotype evaluation and pathogen resistance studies, diversifying the technology’s utility.
Market Opportunities
Increasing Investments in Genomic Research: The U.S. government and private stakeholders are investing heavily in genomic research, with institutions like the National Institutes of Health (NIH) funding initiatives in rare disease genomics. This creates substantial opportunities for HRM analysis developers, such as Qiagen, to collaborate on high-throughput screening projects and clinical trials.
Emergence of Companion Diagnostics: With more targeted therapies being approved, pharmaceutical companies are seeking HRM-enabled companion diagnostics to identify patient subpopulations that would benefit most from specific drugs. This opens doors for diagnostic firms, including Abbott Laboratories, to partner with pharma for co-development opportunities.
North America High-Resolution Melting Analysis Market Revenue (USD Million), 2020–2035
The revenue chart reveals a consistent upward trend in the North America HRM analysis market, with revenue growing from USD 235 Million in 2020 to a forecasted USD 885 Million by 2035. The most significant growth is observed between 2024 and 2030, reflecting the rising adoption of HRM technologies in clinical diagnostics and research, and further boosted by recent regulatory approvals and technological innovations. The compound annual growth rate remains stable at around 7.4%. These figures underscore the increasing demand for accurate and efficient genetic testing methods across various application areas in healthcare and biotechnology.
North America HRM Analysis Market Share by Region (%) - 2025
In 2025, the United States is expected to account for the largest share of the North America HRM analysis market at 68%, owing to its advanced healthcare infrastructure, high R&D expenditure, and early adoption of precision diagnostics. Canada follows with a significant share at 23%, supported by well-equipped research facilities and government investments in genomics. Mexico represents 6% of the market, driven by expanding molecular diagnostics capabilities, while Central America and the Caribbean collectively account for 3%. The pie chart highlights the regional concentration of market opportunities and the dominance of the U.S. in driving innovation and adoption of HRM technologies.
Recent Developments in the North America HRM Analysis Market (Last 6 Months)
In April 2024, Thermo Fisher Scientific launched the QuantStudio 7 Pro HRM Software Update, enabling significantly faster melting curve acquisitions and enhanced data analytics in clinical labs. The update supports regulatory compliance with new FDA guidelines for molecular diagnostic devices, positioning Thermo Fisher as a leader in precise mutation detection.
In March 2024, Bio-Rad Laboratories announced a strategic partnership with a major genomics research institute in Canada to supply HRM assay kits for population-level mutation screening. This partnership aims to utilize Bio-Rad’s advanced qPCR and HRM technologies for studying the genetic causes of hereditary disorders, improving large-scale rare disease diagnostics.
In February 2024, Agilent Technologies introduced cloud-based AI-driven analysis tools for their HRM platforms, supporting automated interpretation of melting profiles and integration with existing laboratory information systems (LIS). Early adopters reported significant improvements in workflow efficiency and diagnostic throughput, demonstrating Agilent’s commitment to digital transformation in molecular diagnostics.
Press Releases